Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Rare Earths Stocks: 9 Biggest Companies in 2024

Uranium Stocks: 5 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

Investing in Graphene Companies (Updated 2024)

Trending Press Releases

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Radiopharm achieves Nasdaq listing of ADS

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

SAGA Metals Completes OTCQB Listing and Receives DTC Eligibility

Significant Milestone Achieved in Development Journey with The Completion of The "first phase" of the Environmental Impact Assessment Procedure for Rajapalot Gold-Cobalt Project

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in the Cobar Basin of New South Wales

More Press Releases
Trending Companies

Purpose Bitcoin ETF

BTCC:CA

Soma Gold Corp.

SOMA:CA

Mount Hope Mining

MHM:AU

First Helium

HELI:CA
More Companies
Trending Reports

2024 Gold Outlook Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

2024 Uranium Outlook

2024 Lithium Market Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Minerva Neurosciences

NSD:NERV
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company.
Press Releases
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Interactive Chart

×